Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2012

View Archived Issues

New antibody could facilitate early diagnosis of neurological disorders

Galectin Therapeutics prepares to advance lead candidate for NASH

DSMBs recommend continuation of ongoing RetinoStat and StarGen trials

NIH designs recombinant oncolytic immunotoxins that may be given at high doses

Investigation reveals new potential target for treating schizophrenia

Merck & Co. divulges novel candidate antihypertensives

Abbott presents new ALK inhibitors

U.S. university patents novel anticancer products

Adynxx completes enrollment in trial of lead pain therapeutic

Alimera Sciences to resubmit Iluvien NDA

Novel FFA2 receptor agonists reported by Galapagos

Ferrer files IND for topical antifungal agent

NICE guideline aims to improve outcome of lower limb peripheral arterial disease

Research at Merck & Co. yields new MR antagonists

NICE issues final guideline on assessing fragility fracture risk in adults

Novel bacterial OMV-based vaccines developed in U.S.

VitroGro CE mark approval application referred to U.K.'s MHRA

Ganitumab studies halted

New ROR1-binding antibodies designed in California

Recruitment complete in phase III OMS-103HP trial

Final data reported from phase II trial of nasal spray for binge eating disorder

Acetylon Pharmaceuticals begins phase Ib trials in multiple myeloma

Dicerna earns milestone payment in oncology collaboration

MJFF issues grant for potential rescue therapy for Parkinson's disease

SPA agreement reached for third phase III trial of oral laquinimod in RRMS

MEI Pharma enters agreement to acquire rights to oral HDAC inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.